Amgen Company Profile (NASDAQ:AMGN)

About Amgen

Amgen logoAmgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company's business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The Company focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. Its products in Phase III programs include Aranesp for Myelodysplastic syndromes; ENBREL for Psoriatic arthritis and Rheumatoid arthritis remission; IMLYGIC for Metastatic melanoma, and Kyprolis for Multiple myeloma.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: AMGN
  • CUSIP: 03116210
Key Metrics:
  • Previous Close: $170.23
  • 50 Day Moving Average: $168.93
  • 200 Day Moving Average: $156.51
  • Trailing P/E Ratio: 17.55
  • Foreward P/E Ratio: 13.78
  • P/E Growth: 1.77
  • Market Cap: $128.37B
  • Outstanding Shares: 748,360,000
  • Beta: 0.83
Additional Links:
Companies Related to Amgen:

Analyst Ratings

Consensus Ratings for Amgen (NASDAQ:AMGN) (?)
Ratings Breakdown: 1 Sell Rating, 9 Hold Ratings, 12 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $185.21 (7.70% upside)

Analysts' Ratings History for Amgen (NASDAQ:AMGN)
DateFirmActionRatingPrice TargetDetails
8/26/2016Leerink SwannReiterated RatingMarket Perform$201.00View Rating Details
8/26/2016Morgan StanleyReiterated RatingOverweight$199.00 -> $198.00View Rating Details
8/26/2016GabelliInitiated CoverageHoldView Rating Details
8/26/2016Robert W. BairdReiterated RatingOutperform$157.00View Rating Details
8/23/2016Jefferies GroupReiterated RatingBuy$198.00View Rating Details
8/5/2016ArgusReiterated RatingBuy$185.00 -> $195.00View Rating Details
7/29/2016Citigroup Inc.Boost Price TargetNeutral$165.00 -> $175.00View Rating Details
7/28/2016Barclays PLCReiterated RatingEqual Weight$185.00View Rating Details
7/28/2016Piper Jaffray Cos.Reiterated RatingBuy$193.00View Rating Details
7/28/2016Credit Suisse Group AGReiterated RatingBuy$206.00View Rating Details
7/28/2016BMO Capital MarketsReiterated RatingOutperform$186.00 -> $190.00View Rating Details
7/13/2016Bank of America Corp.Reiterated RatingHold$182.00View Rating Details
6/29/2016Goldman Sachs Group Inc.Reiterated RatingBuyView Rating Details
6/29/2016Sanford C. BernsteinInitiated CoverageMarket Perform$161.00View Rating Details
5/18/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details
4/17/2016Cowen and CompanyReiterated RatingBuyView Rating Details
2/23/2016BTIG ResearchReiterated RatingSell$135.00View Rating Details
2/22/2016JPMorgan Chase & Co.Reiterated RatingNeutral$165.00View Rating Details
1/22/2016Wells Fargo & Co.Reiterated RatingHoldView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$202.00View Rating Details
9/22/2015NomuraReiterated RatingBuy$190.00 -> $191.00View Rating Details
8/31/2015Raymond James Financial Inc.Initiated CoverageMarket PerformView Rating Details
8/17/2015Deutsche Bank AGReiterated RatingBuy$195.00View Rating Details
(Data available from 8/26/2014 forward)


Earnings History for Amgen (NASDAQ:AMGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/27/2016Q216$2.74$2.84$5.58 billion$5.69 billionViewListenView Earnings Details
4/28/2016Q116$2.60$2.90$5.32 billion$5.53 billionViewListenView Earnings Details
1/28/2016Q415$2.29$2.61$5.53 billion$5.54 billionViewListenView Earnings Details
10/28/2015Q315$2.38$2.72$5.32 billion$5.72 billionViewListenView Earnings Details
7/30/2015Q215$2.43$2.57$5.32 billion$5.37 billionViewListenView Earnings Details
4/21/2015Q115$2.10$2.48$4.91 billion$5.03 billionViewListenView Earnings Details
1/27/2015Q414$2.05$2.16$5.20 billion$5.33 billionViewListenView Earnings Details
10/27/2014Q314$2.11$2.30$4.95 billion$5.03 billionViewListenView Earnings Details
7/29/2014Q214$2.07$2.37$4.90 billion$5.18 billionViewListenView Earnings Details
4/22/2014Q114$1.94$1.87$4.76 billion$4.52 billionViewListenView Earnings Details
1/28/2014Q413$1.69$1.82$4.81 billion$5.01 billionViewListenView Earnings Details
10/22/2013Q313$1.78$1.94$4.60 billion$4.75 billionViewListenView Earnings Details
7/30/2013Q2 2013$1.74$1.89$4.49 billion$4.68 billionViewListenView Earnings Details
4/23/2013Q1 2013$1.84$1.96$4.37 billion$4.24 billionViewN/AView Earnings Details
1/23/2013Q4 2012$1.42$1.40$4.37 billion$4.42 billionViewListenView Earnings Details
10/23/2012$1.47$1.67ViewN/AView Earnings Details
7/26/2012$1.54$1.83ViewN/AView Earnings Details
1/26/2012$1.22$1.21ViewN/AView Earnings Details
10/24/2011$1.29$1.40ViewN/AView Earnings Details
7/29/2011$1.29$1.37ViewN/AView Earnings Details
4/20/2011$1.29$1.34ViewN/AView Earnings Details
1/24/2011$1.11$1.17ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amgen (NASDAQ:AMGN)
Current Year EPS Consensus Estimate: $11.36 EPS
Next Year EPS Consensus Estimate: $12.48 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165$2.48$2.84$2.61
Q2 20163$2.66$2.94$2.77
Q3 20163$2.72$3.12$2.87
Q4 20163$2.64$3.12$2.85
Q1 20171$2.81$2.81$2.81
Q2 20171$2.84$2.84$2.84
Q3 20171$2.89$2.89$2.89
Q4 20171$2.97$2.97$2.97
(Data provided by Zacks Investment Research)


Current Dividend Information for Amgen (NASDAQ:AMGN)
Annual Dividend:$4.00
Dividend Yield:2.33%
Payout Ratio:40.90% (Based on Trailing 12 Months of Earnings)
35.21% (Based on Current Year Consensus EPS Estimate)
32.05% (Based on Next Year Consensus EPS Estimate)

Dividend History for Amgen (NASDAQ:AMGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Amgen (NASDAQ:AMGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/2/2016Annette Louise SuchVPSell3,000$174.59$523,770.00View SEC Filing  
5/4/2016Madhavan BalachandranEVPSell30,000$154.12$4,623,600.00View SEC Filing  
4/29/2016David BaltimoreDirectorSell3,312$157.21$520,679.52View SEC Filing  
4/29/2016Sean E HarperEVPSell21,875$157.99$3,456,031.25View SEC Filing  
8/31/2015Carbonnel Francois DeDirectorSell5,000$153.84$769,200.00View SEC Filing  
8/19/2015Fred HassanDirectorBuy3,010$166.63$501,556.30View SEC Filing  
6/2/2015Cynthia M PattonSVPSell4,530$157.06$711,481.80View SEC Filing  
4/23/2015Stuart A TrossSVPSell3,012$169.31$509,961.72View SEC Filing  
4/22/2015Sean E HarperEVPSell28,000$171.58$4,804,240.00View SEC Filing  
3/3/2015Stuart A TrossSVPSell4,415$157.74$696,422.10View SEC Filing  
3/2/2015David BaltimoreDirectorSell3,647$158.76$578,997.72View SEC Filing  
2/11/2015Robert A BradwayCEOSell22,000$152.69$3,359,180.00View SEC Filing  
2/5/2015Frank C HerringerDirectorBuy3,000$152.29$456,870.00View SEC Filing  
12/3/2014Carbonnel Francois DeDirectorSell3,000$168.01$504,030.00View SEC Filing  
8/5/2014Cynthia M PattonSVPSell2,644$127.97$338,352.68View SEC Filing  
8/5/2014Sean E HarperEVPSell14,000$127.29$1,782,060.00View SEC Filing  
5/21/2014Thomas J.W. DittrichCAOSell4,130$112.83$465,987.90View SEC Filing  
4/28/2014A Kelly MichaelCFOSell2,065$110.45$228,079.25View SEC Filing  
3/6/2014Carbonnel Francois DeDirectorSell1,000$126.69$126,690.00View SEC Filing  
9/4/2013Madhavan BalachandranEVPSell18,000$112.76$2,029,680.00View SEC Filing  
8/28/2013David BaltimoreDirectorSell4,582$109.66$502,462.12View SEC Filing  
5/22/2013Thomas J.W. DittrichCAOSell6,130$104.78$642,301.40View SEC Filing  
5/21/2013Madhavan BalachandranEVPSell6,000$103.28$619,680.00View SEC Filing  
5/17/2013Rebecca M HendersonDirectorSell8,421$105.72$890,268.12View SEC Filing  
5/16/2013Cynthia M PattonSVPSell3,544$105.01$372,155.44View SEC Filing  
5/14/2013Judith C PelhamDirectorSell25,000$108.25$2,706,250.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Amgen (NASDAQ:AMGN)
News IconAnalysts Valuations For Two Stocks: HCA Holdings Inc (NYSE:HCA), Amgen, Inc. (NASDAQ:AMGN) - The Voice Registrar (NASDAQ:AMGN) - August 26 at 3:27 PM
News IconStocks to Keep Your Eyes on: Amgen, Inc. (NASDAQ:AMGN), Splunk Inc (NASDAQ:SPLK) - NYSE Journal (press release) (NASDAQ:AMGN) - August 26 at 3:27 PM logoAmgen, Inc. (AMGN): FDA Complete Response Letter Not Negative: Jefferies - TCC (NASDAQ:AMGN) - August 26 at 3:27 PM
News IconIntraday Active Biotech Stocks News: Arrowhead Pharmaceuticals ... - The Voice Registrar (NASDAQ:AMGN) - August 26 at 3:27 PM logoMorgan Stanley Weighs In on Valeant Pharmaceuticals Intl Inc (VRX) and Amgen, Inc. (AMGN) Following Headquarter ... - Smarter Analyst (NASDAQ:AMGN) - August 26 at 3:27 PM logoAmgen, Inc. (AMGN) Still Has Over 18% Upside Despite Parasabiv CRL: Analyst - TCC (NASDAQ:AMGN) - August 26 at 3:27 PM logo[$$] Don't Expect an Amgen Breakup (NASDAQ:AMGN) - August 26 at 3:27 PM logoFDA Rejection Of Amgen Drug Does Nothing To Change Baird's Outlook On The Stock (NASDAQ:AMGN) - August 26 at 11:38 AM
News IconLeading stocks in today’s market: Amgen Inc. (NASDAQ:AMGN) (NASDAQ:AMGN) - August 26 at 11:38 AM logoMorgan Stanley Weighs In on Valeant Pharmaceuticals Intl Inc (VRX) and Amgen, Inc. (AMGN) Following Headquarter Visit and FDA CRL (NASDAQ:AMGN) - August 26 at 11:38 AM logoLeerink Partners does not see Major Downside for Amgen Inc. (AMGN) Following Parsabiv CRL (NASDAQ:AMGN) - August 26 at 11:38 AM logoAnalyst Downgrades: Amgen, Inc., Teva Pharmaceutical Industries Ltd, and HP Inc - Schaeffers Research (blog) (NASDAQ:AMGN) - August 25 at 8:54 PM logoMylan offers price plan to help patients but its programs are still short on details (NASDAQ:AMGN) - August 25 at 8:54 PM
News IconIntraday Active Biotech Stocks News: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), Amgen Inc. (NASDAQ:AMGN) - The Voice Registrar (NASDAQ:AMGN) - August 25 at 3:32 PM
News IconAnalysts Valuations For Two Stocks: Boston Scientific Corporation (NYSE:BSX), Amgen, Inc. (NASDAQ:AMGN) - The Voice Registrar (NASDAQ:AMGN) - August 25 at 3:32 PM
News IconHC Stocks to watch for: Amgen, Inc. (AMGN), Sanofi SA (ADR) (SNY) - share market updates (press release) (NASDAQ:AMGN) - August 25 at 3:32 PM logoAmgen's Shameful Silence Covers Up Reasons for FDA Drug Rejection (NASDAQ:AMGN) - August 25 at 3:32 PM
News IconAmgen Inc.'s (AMGN): Remarkable Runner - Hot Stocks Point (NASDAQ:AMGN) - August 25 at 8:15 AM logo6:04 pm Amgen: FDA issued Complete Response Letter for its Parsabiv (Etelcalcetide) NDA; company anticipates post-action meeting with FDA later this year (NASDAQ:AMGN) - August 25 at 8:15 AM logoAmgen Provides Update On Status Of Parsabiv™ (Etelcalcetide) New Drug Application (NDA) Submitted To The U.S. Food And Drug Administration (FDA) (NASDAQ:AMGN) - August 25 at 8:15 AM logo[$$] FDA Rejects Amgen Hormonal-Imbalance Treatment (NASDAQ:AMGN) - August 25 at 8:15 AM logoFDA rejects Amgen's Parsabiv NDA for secondary hyperparathyroidism; shares down 1% premarket (NASDAQ:AMGN) - August 25 at 7:43 AM logoTop trades for the 2nd half: Lending Club, Amgen & more (NASDAQ:AMGN) - August 24 at 3:28 PM logoCDSCO Denies Amgen, Inc. (NASDAQ:AMGN) Clinical Trial Waiver For Repatha (NASDAQ:AMGN) - August 24 at 11:46 AM
News IconAmgen Inc. (NASDAQ:AMGN) To Report September 2016 Results - The Voice Registrar (NASDAQ:AMGN) - August 23 at 8:47 PM
News IconIntraday Active Biotech Stocks News: Amgen Inc. (NASDAQ:AMGN), Sequenom Inc. (NASDAQ:SQNM) - The Voice Registrar (NASDAQ:AMGN) - August 23 at 3:31 PM
News IconWorth Watching Stocks - Transocean LTD (NYSE:RIG), Amgen, Inc. (NASDAQ:AMGN) - Money News (press release) (NASDAQ:AMGN) - August 23 at 3:31 PM
News IconHC Stocks Alerts: Anthem Inc (NYSE:ANTM), Amgen, Inc. (NASDAQ:AMGN) - share market updates (press release) (NASDAQ:AMGN) - August 23 at 3:31 PM logoWhy Bernstein Thinks Inflation May Have Bottomed Out (NASDAQ:AMGN) - August 23 at 3:30 PM
News Icon2 Biotech Stocks News And Price Trends: Amgen Inc. (NASDAQ:AMGN), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - The Voice Registrar (NASDAQ:AMGN) - August 22 at 8:36 PM
News IconWorth Watching Stock's Buzzers: Amgen, Inc. (NASDAQ:AMGN), Michael Kors Holdings Ltd (NYSE:KORS) - NYSE Journal (press release) (NASDAQ:AMGN) - August 22 at 3:29 PM
News IconAnalysts Valuations For Two Stocks: Amgen, Inc. (NASDAQ:AMGN), Boston Scientific Corporation (NYSE:BSX) - The Voice Registrar (NASDAQ:AMGN) - August 20 at 3:29 PM logoAMGEN INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhi (NASDAQ:AMGN) - August 20 at 8:26 AM logoGet Ready For Amgen's PDUFA Date For BLINCYTO On September 1 (NASDAQ:AMGN) - August 19 at 11:54 AM logoWill Amgen, Inc. (AMGN) Drug Pipeline Help the Company Grow? - Bidness ETC (NASDAQ:AMGN) - August 18 at 3:38 PM
News IconTop Gainers of the Day: Amgen Inc. (NASDAQ:AMGN) from Biotechnology (NASDAQ:AMGN) - August 18 at 11:52 AM
News IconAnalysts Review on Trending Stock: Amgen, Inc. (NASDAQ:AMGN) - Post Registrar (NASDAQ:AMGN) - August 17 at 3:30 PM
News IconAmgen, Inc (AMGN) - Amgen Stock Is a Powerhouse - (NASDAQ:AMGN) - August 17 at 3:30 PM logoBetter Buy: Amgen Inc. vs. Biogen (NASDAQ:AMGN) - August 17 at 9:13 AM logoCoherus Biosciences Inc (CHRS) Has Set Its Sights On Amgen, Inc. (AMGN) - Insider Monkey (blog) (NASDAQ:AMGN) - August 16 at 3:31 PM logoAmgen, Inc (AMGN) – Amgen Stock Is a Powerhouse - (NASDAQ:AMGN) - August 16 at 3:31 PM
News IconCoherus Biosciences Inc (CHRS) Has Set Its Sights On Amgen, Inc. (AMGN) (NASDAQ:AMGN) - August 16 at 1:34 PM logoAmgen, Sanofi Cholesterol Drugs Not Cost-Effective, Study Says (NASDAQ:AMGN) - August 16 at 12:05 PM logoAmgen, Inc (AMGN) – Amgen Stock Is a Powerhouse (NASDAQ:AMGN) - August 16 at 8:11 AM
News IconAmgen, Inc (AMGN) – Amgen Stock Is a Powerhouse (NASDAQ:AMGN) - August 16 at 7:59 AM
News IconAnalysts Valuations For Two Stocks: Amgen, Inc. (NASDAQ:AMGN), Omnicom Group Inc. (NYSE:OMC) - The Voice Registrar (NASDAQ:AMGN) - August 15 at 3:31 PM logoBiotech Stocks: The Rebirth of the Bull? (NASDAQ:AMGN) - August 15 at 3:31 PM
News IconUpdate on Amgen Inc. (NASDAQ:AMGN) for the day (NASDAQ:AMGN) - August 13 at 11:37 AM logoThird Point adds Facebook position; eliminates Amgen, Kraft (NASDAQ:AMGN) - August 12 at 8:56 PM logoAmgen Inc. (AMGN) Ex-Dividend Date Scheduled for August 15, 2016 - Nasdaq (NASDAQ:AMGN) - August 12 at 3:38 PM


Amgen (NASDAQ:AMGN) Chart for Friday, August, 26, 2016

Last Updated on 8/26/2016 by Staff